The evidence base for gammaCore is small. But cluster headache is a rare condition, and the quality of the studies was good. The committee concluded that gammaCore appears to be effective in some but ...
PRESTO demonstrates clinical benefit of gammaCore in the acute treatment of migraine compared to sham BASKING RIDGE, N.J., Sept. 11, 2017 /PRNewswire/ -- electroCore, a neuroscience and technology ...
ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed ...
BASKING RIDGE, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the FDA has issued an Emergency Use ...
ROCKAWAY, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that its gammaCore™ nVNS device has received ...
A panel of 9 experts, including neurologists, other headache specialists, and medical and pharmacy directors, from 4 health plans (1 integrated delivery network and 3 plans with commercial, Medicare, ...
MIAMI (KFSN) -- Some patients say the pain is worse than childbirth! We're talking about cluster headaches. Now a little device may provide big relief to the more than 350,000 people in the US who are ...
The new approval for migraine patients was supported by the PRESTO trial, a multicenter, randomized, double-blind, sham-controlled trial. GammaCore (nVNS) has been granted 510(k) expanded clearance by ...
JACKSONVILLE, Fla. - Dr. Marshall Bedder was prescribed it all when he was hospitalized with COVID-19. "Antivirals, high-dose steroids, oxygen, inhalers, antibiotics, you name it," he recalled. Bedder ...
electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that the U.S. Food and Drug Administration (FDA) released ...
3 randomised trials: 2 sham-controlled (ACT1, Silberstein et al. 2016, and ACT2, Goadsby et al. 2018) and 1 open label (PREVA, Gaul et al. 2016) 1 post-hoc analysis of a randomised trial (Gaul et al.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results